Pacific Biosciences Of California (PACB) EBITDA Margin Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | -201.00 |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | 586.00 |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | 736.00 |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 887.00 |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | 963.00 |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | 212.00 |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 535.00 |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | 244.00 |
| 10 | Pacific Biosciences Of California | 394.84 Mn | 157.97 Mn | 12.64 Mn | 3,946.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,945.00 |
| Mar 31, 2026 | 21,210.00 |
| Dec 31, 2025 | 22,609.00 |
| Sep 30, 2025 | 12,981.00 |
| Jun 30, 2025 | 7,885.00 |
| Mar 31, 2025 | -92,081.00 |
| Dec 31, 2024 | -21,058.00 |
| Jun 30, 2024 | -36,554.00 |
| Mar 31, 2024 | -9,339.00 |
| Dec 31, 2023 | -6,166.00 |
| Sep 30, 2023 | -2,143.00 |
| Jun 30, 2023 | -1,606.00 |
| Mar 31, 2023 | -2,488.00 |
| Dec 31, 2022 | -25,422.00 |
| Sep 30, 2022 | -10,266.00 |
| Jun 30, 2022 | -9,262.00 |
| Mar 31, 2022 | -5,023.00 |
| Dec 31, 2021 | -2,273.00 |
| Jun 30, 2021 | -2,197.00 |
| Mar 31, 2021 | 744.00 |